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The field of HIV prevention has indeed progressed in leaps and bounds, but with major
limitations of the current prevention and treatment options, the world remains desper-
ate for an HIV vaccine. Sadly, this continues to be elusive, because more than 30 years
since its discovery there is no licensed HIV vaccine. Research aiming to define immuno-
logical biomarkers to accurately predict vaccine efficacy have focused mainly on systemic
immune responses, and as such, studies defining correlates of protection in the geni-
torectal mucosa, the primary target site for HIV entry and seeding are sparse. Clearly,
difficulties in sampling and analysis of mucosal specimens, as well as their limited size
have been a major deterrent in characterizing the type (mucosal antibodies, cytokines,
chemokines, or CTL), threshold (magnitude, depth, and breadth) and viral inhibitory capac-
ity of HIV-1-specific immune responses in the genitorectal mucosa, where they are needed
to immediately block HIV acquisition and arrest subsequent virus dissemination. Nev-
ertheless, a few studies document the existence of HIV-specific immune responses in
the genitorectal mucosa of HIV-infected aviremic and viremic controllers, as well as in
highly exposed persistently seronegative (HEPS) individuals with natural resistance to HIV-
1. Some of these responses strongly correlate with protection from HIV acquisition and/or
disease progression, thus providing significant clues of the ideal components of an effica-
cious HIV vaccine. In this study, we provide an overview of the key features of protective
immune responses found in HEPS, elite and viremic controllers, and discuss how these can
be achieved through mucosal immunization. Inevitably, HIV vaccine development research
will have to consider strategies that elicit potent antibody and cellular immune responses
within the genitorectal mucosa or induction of systemic immune cells with an inherent
potential to home and persist at mucosal sites of HIV entry.
Keywords: HIV-1, HIV vaccines, elite controllers, long-term non-progressors, highly exposed persistently
seronegative, mucosal immunity
INTRODUCTION
The past three decades have witnessed the transformation of
HIV/AIDS from a fatality to a chronic manageable disease but
the situation remains far from ideal as the epidemic continues to
spread. According to the UNAIDS report 2013, an estimated 35
million people are living with HIV, 2.3 million new infections, and
1.6 million AIDS-related deaths were documented at the end of
2012. The field of HIV prevention and treatment has progressed
significantly over the years and has had a huge impact on the HIV
pandemic. Anti-retroviral therapy (ART), more especially highly
active ART (HAART) has been quite instrumental in the fight
against HIV/AIDS and represents the most significant achieve-
ment that has transformed an epidemic that threatened to wipe
out humanity (1). HAART has not only increased the lifespan
of infected people (2), but has had other significant health ben-
efits including reduced risk of opportunistic infections such as
tuberculosis and AIDS-defining cancers, namely Kaposi sarcoma
and cervical cancer (1, 3). Moving a notch higher, pre-exposure
prophylaxis (PrEP) and post-exposure (PEP) trials demonstrate
outstanding success as evidenced by significant reductions in the
risk of HIV-1 infection via heterosexual and homosexual trans-
mission, as well as injecting drug usage (4–8). In breakthrough
infections, however, early treatment not only provides an immune
advantage such as functional cure demonstrated in a few stud-
ies including the VISCONTI study, the Mississippi baby, and the
recently reported Long Beach baby (9–12), but also dramatically
reduces the risk of secondary transmission as demonstrated in
studies with sero-discordant couples, where the infected part-
ner initiates early treatment (13) and studies the prevention of
mother-to-child transmission (MTCT) (14, 15).
The recent introduction of universal testing and treatment
(UTT) followed by immediate initiation of ART to all those testing
HIV positive irrespective of clinical stage or CD4 count (16–19)
will have a huge impact on the epidemic, although the reality
is that wider scale implementation will inevitably be logistically
and financially overwhelming (20). Microbicides (8) and male
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circumcision (21–23) have also contributed significantly to the
reduced risk of infection and/or transmission, and have great
potential if deployed on a larger scale. Despite the tremendous
progress in the field, challenges remain and a vaccine is still of
top most priority. An HIV vaccine would not only ease the cost
of burden of therapy globally, but will also have a huge public
health impact. Experts agree that a comprehensive package com-
bining an effective, safe, well-tolerated, accessible, and affordable
HIV vaccine with HAART, and the current HIV preventive tech-
nologies would ultimately bring the epidemic to an end. Thus, a
combination of prophylactic and therapeutic vaccines that prevent
infection and afford superior control of viremia in breakthrough
infections will significantly reduce the spread of infection and dis-
ease (3). The successful HIV vaccine candidates are expected to
induce potent broadly neutralizing antibodies (bNAbs) and high
titers of non-neutralizing antibodies, in addition to robust cel-
lular immune responses with virus inhibitory effector functions
in order to offer long-lasting sterilizing immunity, or in the case
of breakthrough infections, to at least increase the threshold of
HIV titers required for infection, reduce virus load setting point,
and reduce secondary transmission rates (24–28). Most impor-
tantly, since a significantly large proportion of HIV infections are
transmitted sexually, both heterosexual (29, 30) and homosexual,
especially in men who have sex with men (31), prophylactic vac-
cine candidates should be effective at all possible portals of HIV-1
entry, with key focus on the genital and rectal mucosa (32).
HIV-1 VACCINE CANDIDATES: PROGRESS SO FAR
Several factors that have rendered HIV vaccine design an unprece-
dented challenge have been extensively discussed in several inde-
pendent reviews. These factors include the enormous HIV virion
diversity (up to 35% in gp120) culminating in many HIV-1 sub-
types/clades and circulating recombinant forms (33, 34); the well-
documented immune evasion strategies (35) and immune escape
(36); persistence of the virus in latent reservoirs that cannot be
effectively cleared with HAART (37, 38); the immunoregulatory
facet of HIV comprising memory CD4+ T-cell depletion from
mucosal sites including the gut-associated lymphoid tissue (GALT)
(39, 40) and MHC class 1 down-regulation by Nef (41) among oth-
ers; and the overall lack of definitive correlates of immune protec-
tion coupled with imperfect correlations or discrepancies between
systemic and mucosal immune responses (42–45). Despite these
challenges, the field of HIV vaccine trials has evolved over the
years, and currently, more than 200 vaccine trials (IAVI Clinical
Trials Database 2014: http://iavireport.org/Trials-Database) have
been conducted since the launch of the first ever HIV vaccine trial
in the mid 1980s (46). Of these, a few vaccine candidates that
showed modest immunogenicity in the initial stages of evaluation
were implemented at Phase IIb and III to test their efficacy in HIV
control (summarized in Table 1). These vaccines were designed to
induce T cells alone (HVTN502 and HVTN503), T cells in com-
bination with antibodies (HVTN505 and RV144), or antibodies
alone (VAX003 and VAX004).
The major goal of T cell vaccines is to induce and maintain a
high level of potent and fully functional effector T cells that will
rapidly become home to mucosal sites, the first portal of entry, and
abort early HIV infection (54). Evaluation of MRKAd5 vaccine
(gag/pol/nef) in the STEP (HVTN502) and Phambili (HVTN503)
Phase IIb trials demonstrated induction of relatively strong and
durable T cell responses (47, 55); however, in both studies, the
vaccine failed to prevent infection or control early viremia in
breakthrough infections. Further analysis of breakthrough infec-
tions uncovered the existence of vaccine-induced selective pressure
(56), suggesting a strong vaccine-induced immune response, and
also highlighting the possibility that limited breadth of vaccine-
stimulated responses might have impacted on the potential to con-
tain virus replication during acute infection. A carefully designed
follow-on Phase IIb clinical trial (HVTN505) that tested a multi-
clade immunogen expressing gag/pol/nef/env was also halted for
futility (49). This vaccine induced both T cell and antibody
responses (strong IgG binding antibodies to gp140), as well as
some neutralizing activity, but clearly these did not correlate with
protection, and were instead skewed toward increased risk of
HIV acquisition. Although the failure of these vaccines to protect
against infection and the unexpected association with increased
risk of HIV acquisition are a huge setback in the development
of T cell vaccines, there is still cause for optimism, as follow-up
analysis of the HIV-infected STEP study participants revealed a
correlation of vaccine-induced Gag-specific T cells with reduced
plasma viremia, independent of HLA influence (57). Furthermore,
we have recently demonstrated induction of broad and very high
magnitude, polyfunctional CD8+ and CD4+ T cell responses in a
Phase I clinical trial of a T cell vaccine candidate (HIVconsv),
expressing gag/pol/vif/env sequences that were assembled from
the most conserved regions of HIV-1 (58, 59). Of key impor-
tance is the observation that HIVconsv vaccine-induced CD8+
effector T cells could recognize HIV-infected autologous CD4+ T
cells and achieved up to 5.79 log10 inhibition of virus replication,
suggesting that such vaccine-induced cytotoxic T cells may have
great potential to impact post-infection virus replication. Indeed,
these findings were corroborated in a challenge study where rhesus
macaques immunized with SIVconsv (an equivalent of HIVconsv)
showed robust and polyfunctional T cell responses that protected
them from the pathogenic SIVmac251 (60). Independently, a T
cell-based vaccine expressing SIV Gag was shown to elicit high
magnitude, broad, and polyfunctional cellular immune responses
that were associated with reduced SIVmac251 virus load set point,
as well as decreased AIDS mortality (61). However, the efficacy of
HIVconsv in preventing HIV-1 acquisition or lowering virus set
points remains to be tested in efficacy trials, and if achieved, will
be a significant milestone for T cell vaccines.
As it is speculated that sterilizing immunity against HIV-1
will largely depend on induction of potent bNAbs (in combi-
nation with strong antiviral T cell responses), antibody-based
vaccines remain attractive in HIV vaccine development strategies
although their potential benefit in terms of preventing HIV acqui-
sition or controlling replication in humans is yet to be sufficiently
demonstrated (51–53). These Phase III clinical trials (VAX003 and
VAX004) tested the monovalent subtype B and bivalent subtype
B/E rgp120 vaccines and showed induction of complex and robust
immune responses comprising binding and neutralizing antibody
responses to gp120 (Table 1), but no reduction in the incidence
of HIV-1 was observed among the vaccinees. Although the high-
risk nature of VAX003 and VAX004 trial participants might have
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Table 1 | Phase IIb and III HIV vaccine efficacy trials.
Vaccine trial Vaccine candidate
and immunogens
Specimens collected Most significant immune
response elicited
Reference
Systemic Mucosal
HVTN 502/Merck 023 STEP
Study (Phase IIb/prophylactic)
MRKAd5 HIV-1
gag/pol/nef
Serum, plasma,
PBMCs
Not
collected
T cell response Buchbinder et al.
(47)
HVTN 503 Phambili Study
(Phase IIb/prophylactic)
MRKAd5 HIV-1
gag/pol/nef
Serum, plasma,
PBMCs
Not
collected
T cell response Gray et al. (48)
HVTN 505 (Phase
IIb/prophylactic)
VRC-HIVDNA016-00-VP/
VRC-HIVADV014-00-VP
Serum, plasma,
PBMCs
Not
collected
T cell and antibody responses
(gp140 binding IgG)
Hammer et al.
(49)
RV144 (Phase III/prophylactic) ALVAC-HIV vCP1521/
AIDSVAX-gp120 B/E
Serum, plasma,
PBMCs
Collected
but inade-
quate
T cell and antibody responses
(non-neutralizing antibodies to
the V1/V2 loop)
Rerks-Ngarm
et al. (50)
VAX 003 (Phase
III/prophylactic)
AIDSVAX B/E (gp120) Serum, plasma,
PBMCs
Not
collected
Antibody response (binding and
neutralizing antibodies to gp120)
Pitisuttithum
et al. (51)
VAX 004 (Phase
III/prophylactic)
AIDSVAX B/B (gp120) Serum, plasma,
PBMCs
Not
collected
Antibody response (binding and
neutralizing antibodies to gp120)
Flynn et al. (52),
Gilbert et al. (53)
PBMCs, peripheral blood mononuclear cells.
had an influence on vaccine efficacy, the failure of these trials still
highlighted legitimate limitations of antibody-based vaccines, in
terms of preventing HIV acquisition or post-infection virus repli-
cation. Nonetheless, studies in non-human primates (NHPs) have
provided solid evidence that bNAbs can be very effective in the
control and elimination of experimental SIV or SHIV infections
(62–64). This has paved way for the identification and isolation of a
number of potent and broadly neutralizing monoclonal antibodies
(65–71), as discussed in later sections.
Although the focus is largely on bNAbs, non-neutralizing anti-
bodies may potentially play a significant role in HIV-1 acquisition
and progression by acting via Fc-receptor-mediated binding of
infected cells to trigger recruitment of effector cells with cellu-
lar cytotoxic activities such as antibody-dependent cell-mediated
cytotoxicity (ADCC) or secretion of antiviral cytokines that inhibit
virus replication, i.e. antibody-dependent cellular virus inhibition
(ADCVI) (72, 73). Vaccine challenge studies in NHPs revealed
a correlation of such antibody-dependent cytotoxicity and viral
inhibition with reduced viral loads (74–77), thus demonstrating
their potential involvement in protection. Furthermore, high lev-
els of ADCC-mediating antibodies correlate with HIV suppression
in elite controllers (78). The protective effect of non-neutralizing
antibodies was indeed confirmed in the Thai Phase III RV144 trial,
where potent non-neutralizing antibodies to the V1/V2 loop cor-
related significantly with protection from HIV acquisition (50, 79,
80). Additionally, correlation of ADCC with reduced risk of infec-
tion was also confirmed (79). The RV144 study tested the safety
and efficacy of a prime-boost regimen comprising an ALVAC-HIV
(a canary pox vector expressing HIV-1 env/gag/pro) prime and
AIDSVAX-gp120 B/E (recombinant gp120) boost in heterosexual
individuals at various levels of risk of HIV infection. These vac-
cines were designed to induce both antibody and cell-mediated
immune responses and to complement each other in order to
maximize protection. Hence, with 74 HIV infections among the
placebo recipients compared to only 51 in the vaccinees, RV144
achieved 31.2% efficacy and although there was no effect on viral
load following infection, it so far remains the most encouraging
vaccine study to date. Thus, although highly elusive, the unsatis-
factory outcomes of three large clinical trials (47–49, 55, 81) mean
that now more than ever, the world is more desperate for a safe
and an effective vaccine to prevent HIV infection and/or control
progression to AIDS.
NOVEL VACCINE DESIGN AND DELIVERY STRATEGIES TO
IMPROVE IMMUNOGENICITY AND EFFICACY
As much as poor immunogenicity might be blamed for the appar-
ent lack of efficacy of several HIV vaccine candidates tested to
date, the observation that vaccine-induced immune responses
consistently waned over time suggests that even with the most
immunogenic of vaccines, protection may be limited to only those
individuals who get exposed to HIV-1 within the first few months
following immunization. Although this can be effectively over-
come by multiple booster immunizations, the costs and compli-
ance issues will certainly be prohibitive. Therefore, novel strategies
that circumvent these pre-existing hurdles are urgently required
in order to design vaccines with improved immunogenicity and
long-term efficacy. For instance, it is anticipated that strategies
targeting the B cell maturation pathway to induce preferential
maturation of naïve B cell precursors of potent and bNAbs could
achieve long-term protection against HIV acquisition and dis-
semination (82, 83). Additionally, adjuvants that activate enzymes
regulating somatic mutation, such as activation-induced cytidine
deaminase (AID),could be utilized to potentially boost the chances
of producing bNAbs (84). Durability of antibody responses may
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be enhanced by use of vectored immunoprophylaxis, an approach
where immunoglobulin genes are inserted in a viral vector, which
then provides life-long expression of high titers of the respec-
tive monoclonal bNAbs following a single intramuscular injection
(85). The success of this strategy has been very recently demon-
strated in a study using adeno-associated virus (AAV) encoding
bNAbs against HIV, which was shown to induce prolonged anti-
body expression and long-lasting protection of humanized mice
from high-dose intravenous and vaginal challenges with diverse
HIV strains (85, 86).
Cytokines that can directly enhance B cell maturation into long-
lived antibody-secreting cells (ASC), such as IL-4, IL-5, and IL-6,
may be used as genetic adjuvants to increase NAb titers. The effi-
cacy of this approach is documented by a Friend virus challenge
study where co-delivery of adenovirus vectors encoding IL-5, IL-
6, or IL-23 together with adenoviral vector expressing the Friend
virus surface envelope protein gp70 (Ad.pIXgp70) significantly
controlled virus replication and enhanced protection (87). In
particular, mice co-immunized with IL-5 and IL-23-encoding ade-
noviruses produced higher titers of NAbs (87). Genetic adjuvants
encoding type 1 interferons (IFNs) (88) and certain chemokines
such as CCL3, CCL19, and CCL28 (89, 90) were also found to
improve adenovirus vector-mediated immunity to Friend virus.
Chemokines that attract specialized antigen-presenting cells can
thus enhance vaccine uptake and increase the magnitude of the
immune response. When adenovirus vector encoding CCL3 (a
DC chemo-attractant) was co-delivered with adenovirus vectors
expressing gag/env antigens of Friend virus, improved protection
that correlated with enhanced virus-specific CD4+ T cells and
higher NAb titers was observed (89). Similarly, CCL3 co-delivery
of HIV antigens (gag/pol/env) induced higher titers of HIV-specific
binding and neutralizing antibodies compared to delivery of anti-
gens alone (89). Co-delivery of CCL19 and CCL28 significantly
augmented mucosal and systemic antibody responses and also
enhanced their neutralizing activity against homologous and het-
erologous HIV-1 strains (90). Thus, the adjuvant effect of these
cytokines and chemokines could be synchronized with antigen
delivery to enhance HIV vaccine efficacy.
Following the recent demonstration that contrary to the
non-replicating adenovirus vector, a replicating cytomegalovirus-
vectored vaccine offered superior protection of rhesus macaques
from repeated mucosal challenges with the highly pathogenic SIV-
mac239 (91), the focus is shifting toward live vectors that induce
stable effector memory rather than central memory CD8+ T cell
responses (92). Seemingly, persistent but low-level replication of
vaccine delivery vectors not only correlates with stimulation of
potent effector memory T cells with enhanced antiviral capacity,
but also provides stable immune-surveillance capable of clearing
latent viral reserves (93). Such like vectors hold great promise
for successful HIV vaccines, although they will need to be care-
fully selected to avoid induction of active disease in vaccine
recipients, or possible antagonism of vaccine-elicited immune
responses.
Immunological pressure exerted on HIV by vaccine-stimulated
CD8+ T cells is thought to have caused early viral escape and
contributed to the lack of protection among the STEP study vac-
cinees. Thus, vaccine approaches utilizing immunogens that are
derived from conserved regions of HIV-1 (58, 59) or conserved
consensus mosaics (94, 95) may possibly limit escape and offer
better protection. Mosaic vaccines are designed to maximize cov-
erage of global antigen epitopes and to therefore overcome HIV
diversity by eliciting broad multi-clade immune responses (95, 96).
Such increased diversity of immunogens (multiple epitopes and
their variants) greatly increases the chances of matching vaccine-
induced immune responses to the antigenic phenotype of the
infecting founder virus or circulating HIV strains. Mosaic vaccines
have shown great promise in NHP studies where comparatively
superior breadth and depth of T cell responses was demonstrated
(94, 97, 98). Furthermore, polyvalent mosaics were shown to
induce both neutralizing antibodies and cellular responses (99),
which effectively protected animals from high-dose challenge
infections and were also effective at controlling breakthrough virus
replication. Thus, to overcome the problem of enormous HIV
diversity, while at the same time improving longevity of vaccine-
stimulated immunity, a combination of replicating vectors (with
an excellent safety profile) with both T cell- and antibody-inducing
mosaic vaccines might be a much better strategy.
HIV infection activates immune regulatory pathways by
increasing the frequency of regulatory T cells (Tregs) and gen-
eration of functionally impaired, exhausted CD8+ and CD4+
T cells which are inadequate to control virus replication and
prevent disease progression (100). Thus, strategies that could
enhance immunogenicity and overall vaccine efficacy, with par-
ticular emphasis on the control of breakthrough infections, may
include concurrent depletion of Tregs and blockade of inhibitory
pathways such as the programed death-1/ligand (PD-1/PD-L1)
and the T cell immunoglobulin and mucin protein 3 (Tim-3) path-
ways during immunization. These strategies function to overcome
negative regulation and restore immune function in exhausted T
cells, and may be particularly attractive in therapeutic vaccines for
HIV-1 where they could reduce virus loads and help to maintain
an aviremic state (101, 102).
CORRELATES OF PROTECTION AGAINST HIV/AIDS
Despite intensive research, immunological biomarkers that could
accurately predict reduced HIV-1 acquisition and transmission are
not yet defined, thus making it a huge challenge to gage the poten-
tial efficacy of HIV vaccine candidates prior to the costly large-scale
efficacy trials. This is further complicated by the fact that there is
not a single documented case of immune-mediated HIV-1 clear-
ance in infected individuals. Although the recent RV144 trial has
provided significant clues of possible correlates of risk versus pro-
tection (79), the limited number of infected vaccinees studied
makes it hard to draw definitive conclusions. Thus, attempts to
define immune correlates of protection are still based on data
largely arising from studies of long-term non-progressors (LTNPs)
and HIV controllers, a rare group of individuals comprising both
elite and viremic controllers with spontaneous HIV-1 control in
the absence of treatment (103) and also from individuals who
are highly exposed to the virus but remain persistently uninfected
highly exposed persistently seronegative (HEPS) such as commer-
cial sex workers, the uninfected partners of sero-discordant cou-
ples, or exposed healthcare providers. These studies have unraveled
a number of protective factors which can be broadly divided
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into two categories, namely host/viral-related or immune-related
factors, and are discussed in detail below.
HOST GENETIC FACTORS THAT CORRELATE WITH PROTECTION
Data from large numbers of non-progressor/slow progressor
cohorts indicate that protective HLA alleles such as HLA-B27,
HLA-B51, HLA-B57 and HLA-B58 which are associated with bet-
ter virus control are overrepresented in these groups, thus impli-
cating a very strong role for host genetics in the course of HIV
infection and disease (104–106). Incidentally, genome-wide asso-
ciation and HLA class 1 analysis of HIV-specific T cell responses
in the MRKAd5 vaccinees revealed that high-magnitude responses
were associated with HLA-B27, -B51 and -B57,while HLA-B08 and
-B45 were associated with lower level responses (107). Other host
genetic factors such as the CCR5∆32 and CCR2-64I mutations
in chemokine receptor genes (108–110) as well as the killer-cell
immunoglobulin-like (KIR) receptor polymorphisms (111–115)
have also been associated with slow progression or resistance to
infection (116). In fact individuals who are homozygous for the
32 base pair deletion in CCR5 are completely protected from HIV
infection, and the protective function of this mutation has been
recently demonstrated in the only patient to achieve sterilizing
cure of HIV-1 following stem cell transplant from a CCR5∆32
homozygous donor (117–120). Additionally, there are intrinsic
host-resistant factors such as the restriction factors TRIM-5α,
APOBEC3G, SAMHD1, and tetherin (121–123), which control
HIV replication through various mechanisms, and any genetic
alterations in their expression levels or patterns can alter the rate
of HIV acquisition and progression (124, 125). However, it is
imperative to note that the presence of these protective factors,
chemokine receptor mutations, or HLA haplotypes per se, is not
sufficient to confer a slow progression phenotype, as several stud-
ies indicate rapid progression of some infected individuals bearing
these protective HLA and KIR genotypes. Additionally, it is known
that some individuals without these protective genetic character-
istics control HIV replication or persistently evade infection, thus
strongly implicating alternative explanations for the attenuated
disease course, such as immune-mediated protection.
IMMUNE-MEDIATED CORRELATES OF PROTECTION
Studies of HIV-infected controllers indicate that robust, broadly
directed, highly proliferative, polyfunctional cytotoxic CD8+ and
CD4+ T cell responses target conserved regions of HIV-1 such as
Gag correlate with reduced virus replication (126–134). In particu-
lar, CD8+ T cells from HIV-1 controllers display enhanced capac-
ity to inhibit HIV-1 replication (129, 135–138) either via direct
killing of infected cells or by secretion of antiviral factors known
to suppress HIV replication (139). These cells also produce higher
levels of IL-2 (140), have superior capacity for clonal expansion,
and contain more granzyme B and perforin (138, 141). In some
cases, these cells can exhibit the exceptional capacity to supress
viral replication in vitro without prior antigen re-stimulation (127,
129). However, it is worth noting that although control of HIV-1
in various independent (but small) slow progressor cohorts corre-
lates significantly with enhanced magnitude and breadth of T cell
responses, a study looking at a larger sample size (n= 124) of well-
defined elite controllers showed that elite control of HIV-1 was in
fact associated with the lowest magnitude and breadth of IFN-
γ responses, as well as the lowest titers of broadly cross-reactive
neutralizing antibodies (142). This confirms that the quality of the
response rather than the quantity remains important in virus con-
trol. Thus, in agreement with other studies, preferential targeting
of Gag and co-secretion of both IFN-γ and IL-2 were correlated
with virus control among the elite controllers than the chronic
progressors and viremic controllers in this study (142).
In addition to controlling virus replication, it has recently
been reported that HIV-specific CD8+ CTLs are an absolute
requirement for the elimination of latent viral reservoirs follow-
ing reactivation (143). Since elite controllers harbor significantly
lower latent viral reservoirs (144–146), this suggests a strong
link between the presence of HIV-specific CD8+ T cells with
potent cytotoxic activity and controlled latency. Indeed, this was
confirmed in a very recent study which demonstrated the excep-
tional ability of primary CD8+ T cells from elite suppressors to
effectively eliminate precursors of latently infected cells (147).
Moreover, elite controllers are known to develop potent effec-
tor memory (T EM) rather than central memory (T CM) T cells
(148) which are not only more effective at suppressing viral control
but are also known to resist apoptosis, thus capable of protecting
against disease progression and establishment of latent reservoirs
for extended periods in the absence of HAART (103, 149–151).
Besides T cells, natural killer (NK) cells, known to inhibit HIV
replication through a variety of mechanisms (152), are also numer-
ically elevated in blood of HEPS, where they are thought to protect
from HIV-1 acquisition by secretion of antiviral factors (153–155).
Indeed, increased production of pro-inflammatory cytokines such
as TNF-α and IFN-γ by KIR3DL1/HLA-Bw4 NK cells is asso-
ciated with lower viral loads and slower progression of infected
individuals (113, 156, 157). Moreover, preserved NK cell func-
tion (which is lost in progressive HIV-1 infection) has been linked
with asymptomatic HIV-2 infection (158). Also, increased lev-
els of the beta-chemokines RANTES, MIP-1α, and MIP-1β, all of
which are known to bind the HIV-1 co-receptor, CCR5, is linked
with protection from HIV acquisition in cohorts of high-risk
women (159, 160). These chemokines have been directly associ-
ated with resistance to HIV-1 infection, reduced viral replication,
and subsequently delayed disease progression (161–163).
The studies described in this section mainly relate to systemic
immune responses. However, it is vital that immune-mediated cor-
relates of protection in the genitorectal mucosa are characterized
since they are indispensable in defining the overall efficacy of HIV
vaccines. The next section briefly highlights the immune responses
found in the genitorectal mucosa that have been correlated with
protection.
IMMUNE-MEDIATED CORRELATES OF PROTECTION IN THE
GENITORECTAL MUCOSA
The observation that multiple exposures to high virus load is
required for successful heterosexual HIV-1 transmission suggests
the existence of robust mucosal innate immunity that must be
actively involved in the control of HIV-1 infection and virus
dissemination. Thus, immune responses at the genital mucosa
especially those of the innate immune system provide the first line
of defense and are critical in preventing HIV-1 infection (164)
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or destruction of HIV-1 target cells at the mucosa, before the
development of adaptive immune responses. Plausibly, vaccine-
mediated stimulation of components of the innate immune system
such as dendritic cells, NK, and NKT cells as well as macrophages
in the genitorectal mucosa could have a significant reduction in
HIV-1 acquisition by production of antiviral cytokines such as
type 1 IFNs or even by acting through ADCC to destroy infected
cells. Alternatively, the type 1 IFNs together with other cytokines
including IL-15 and IL-18 can serve to augment both innate and
adaptive immune responses. However, this review will only dis-
cuss the adaptive humoral and cell-mediated immune responses to
HIV-1 in the genitorectal mucosa as they form a significant part of
the critical determinants of vaccine-induced immunity and might
therefore hold the key to accelerating HIV-1 vaccine development.
Several HIV-1 vaccine candidates tested for immunogenicity and
efficacy up to advanced stages (Table 1) did not yield any mucosal
data (165), especially the RV144 trial, the only one to show vaccine
efficacy. As such, the definitive correlates of vaccine efficacy in the
genital mucosa still remain unknown. This section discusses the
various mucosal immune responses which have been linked with
natural resistance to HIV-1 in HEPS or attenuated disease course
in HIV controllers.
PROTECTIVE CELLULAR IMMUNE RESPONSES IN THE GENITORECTAL
MUCOSA
A large body of evidence documents the existence of HIV-specific
cellular immune responses in blood of HEPS (166–170), although
there have been lots of skepticism concerning the occurrence of
adaptive immune responses without active HIV infection or repli-
cation. It has been speculated that these responses arise from
abortive (failed) infections that are effectively cleared before the
virus successfully establishes its reservoirs. A study designed specif-
ically to address the question as to whether HEPS truly make
HIV-specific T cell responses recruited sero-discordant couples
in Malawi (HPTN 052 cohort) and in the UK (CHAVI 002, St.
Mary’s cohort) and used a very sensitive (cultured Elispot) assay
able to detect very low frequency T cell responses (171). This
study confirmed the existence of HIV-specific CD8+ and CD4+
T cell responses that were mapped to T cell epitopes frequently
targeted in HIV-infected individuals. Interestingly, the responses
were maintained across multiple visits in the absence of HIV infec-
tion, as no virus could be detected even with the highly sensitive
transcription-mediated amplification assay (TMA). A recent study
of sero-discordant couples in Uganda reported similar findings
(172), thus confirming that exposure to HIV can prime adaptive
immune responses that can be boosted by repeated exposures.
There is also strong evidence that mucosal HIV-specific CD8+
and CD4+ T cells modulate HIV-1 disease course, as they can
control post-infection virus replication and persistence by directly
killing infected target cells or secreting a number of antiviral
cytokines. IFN-γ-producing HIV-specific CD8+ T cells found in
the genital mucosa of HEPS were thought to be responsible for
their natural HIV-1 resistance (173). This study also revealed an
enrichment of IFN-γ-producing HIV-specific CD8+ T cells in the
cervical mucosa as opposed to the systemic compartment, thus
strongly suggesting a role in protection against HIV-1 acquisition.
However, although multiple exposures to replication-competent
HIV-1 is well-documented in these individuals, in the absence
of confirmed productive HIV-1 infection, it is difficult to judge
whether the existence of HIV-specific T cells is indeed cause
of HIV-1 resistance or merely a marker of exposure. Never-
theless, human studies assessing immune responses in mucosal
compartments of HIV-1 infected individuals revealed an inverse
correlation of magnitude and poly-functionality of rectal HIV-1
Gag-specific CD8+ and CD4+ T cell responses and viral load (45,
174, 175), highly suggesting that mucosal T cells do exert anti-HIV
activity in the rectal mucosa. Elite control of HIV was signifi-
cantly associated with strong and polyfunctional T cells, secreting
CD107a and MIP-1-β among other cytokines. Intriguingly, the
mucosal immune responses in HIV-1 controllers were significantly
higher and more polyfunctional than those in progressors, while
the systemic immune responses remained indistinguishable (45).
These observations highlight the potential discrepancies between
blood and mucosal immune responses and further demonstrate
the importance of generating protective immune responses within
the local sites of virus entry.
PROTECTIVE HUMORAL IMMUNE RESPONSES IN THE GENITORECTAL
MUCOSA
HIV-specific mucosal IgG and IgA antibodies, especially those
with demonstrated HIV-1-neutralizing activity form the pillar that
protects against HIV-1 acquisition, at least in cohorts of highly
exposed seronegative individuals (176–180). These antibodies can
act by inhibiting various mucosal HIV-1 entry pathways such as
epithelial transcytosis (181, 182) and by binding to the HIV-1 virus
or by neutralizing the virus to prevent infection of CD4+T cells by
primary HIV-1 isolates (183). Alternatively, they could also serve
to aggregate HIV virions and inhibit movement through cervical
mucus. Contrary to individuals with progressive HIV-1 infection,
the IgA antibodies found in HEPS mainly recognize the conforma-
tionally conserved regions of the gp41 subunit of HIV-1 envelope,
thus indicating potential for cross-clade neutralization (178, 184,
185). HIV-specific IgA with potential neutralizing activity (179,
186) has been detected in the cervico-vaginal secretions of women
(176, 187, 188) and urethral swabs of heterosexual men (189) with
natural HIV-1 resistance, indicating a possible role in blocking
HIV-1 acquisition. In a recent study, HIV-1-neutralizing IgA was
found in the cervico-vaginal secretions of highly exposed seroneg-
ative women in a prospective discordant couple cohort study (190),
thus providing definitive evidence of antiviral activity in mucosal
secretions after HIV-1 exposure. One major shortcoming is that
maintenance of adequate levels of these antibodies requires con-
tinuous exposure to HIV-1 (186), suggesting perhaps a lack of
effective formation of memory B cells. Despite the encouraging
neutralization activity of HIV-1-specific IgA antibodies and the
fact that secretory IgAs are a major component of the mucosal anti-
body responses, not many IgA monoclonal antibodies have been
isolated. However, one study indicates that human monoclonal
Fab IgAs directed at gp41, which were constructed by genetic engi-
neering of mucosal cervical B lymphocytes from HEPS, exhibited
good neutralization potential and were more potent at blocking
transcytosis (183). The protective effect of such conserved and
naturally induced antibodies implicates them as desirable com-
ponents of mucosal HIV-1 vaccines, where they can potentially
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abort HIV-1 infection by targeting cell-free virus to prevent entry
into mucosal tissues. This concept was demonstrated in an ani-
mal study where a gp41 subunit HIV-1 vaccine-induced vaginal
IgAs capable of blocking transcytosis, as well as vaginal IgGs with
neutralizing or ADCC activities (43). These antibodies provided
sterilizing immunity in Macaca mulatta monkeys challenged with
SHIV-SF162P3, in the absence of systemic neutralizing antibodies,
again reinforcing the importance of generating immune responses
in the genitorectal mucosa.
The studies described here convincingly demonstrate that these
immuno-functional parameters are predictive of slow progression
in a majority of HIV controllers or sterile protection in those indi-
viduals who resist HIV-1 infection despite multiple exposures to
high doses of intact replication-competent HIV-1 viruses (171).
Therefore, it is plausible that vaccine strategies that can induce
such immune responses would have a significantly greater chance
of either preventing infection or achieving functional cure in
breakthrough infections. This was to some extent demonstrated in
the STEP trial where vaccine-induced T cells correlated with virus
control in a few of the infected vaccinees (57). Thus, collectively,
these observations indicate that a myriad of factors encompassing
host genetics, immunological parameters, and viral determinants
act together to bring about the attenuated disease course (103,
191) or resistance to HIV. However, although it is conceivable
that vaccines can be engineered to mimic protective immune
responses, little can be done to influence the host genetic fac-
tors. Therefore, vaccine development efforts need to focus on the
induction of mucosal (and systemic) immune responses which
confer protection independent of host genetic factors.
CORRELATES OF IMMUNE PROTECTION IN THE CONTEXT OF
VACCINE EFFICACY: ARE THEY RELIABLE?
To put all these into the context of vaccine efficacy, it is worth a
reminder that despite the documentation of immune responses
that seemingly correlate with virus control in infected or highly
exposed uninfected individuals, the ultimate proof of correlates of
protection can only come from efficacy trials in humans. Can we
say that so far the predicted correlates of protection have trans-
lated into vaccine efficacy? As an example, protection in the RV144
trial was not related to bNAbs or strong CD8+ CTL responses
as both of these were not detected. Instead only CD4+ T cells,
ADCC and neutralizing antibodies to the easy to neutralize tier-1
viruses were observed. Furthermore, the RV144 trial revealed that
although high levels of plasma IgG antibodies targeted to the vari-
able regions V1/V2 loop of the envelope gp120 were associated
with protection against HIV-1 acquisition, envelope-specific IgA
antibodies actually mitigated the effects of protective antibodies
and were associated with increased risk of infection (79).
Incidentally, high levels of such IgA-binding antibodies to
gp140 were also detected in the HVTN505 study vaccinees, where
they are speculated to have influenced the risk of HIV acquisition
(49). These observations immediately prompt the need to further
investigate the role of IgA in HIV-1 acquisition since it has been
significantly associated with mucosal immunity to HIV-1 in sev-
eral studies of HEPS (188, 190, 192). Moreover, these observations
indicate that protection from infection is not necessarily mediated
by neutralizing antibodies or robust CTLs as inferred from studies
in HEPS, elite controllers, and LTNPs, thus emphasizing the need
to re-define correlates of protection, and perhaps keenly study the
role of non-neutralizing antibodies in protection versus risk. It is
possible that vaccines inducing high levels of IgG and lower levels
of IgA, concurrently with broadly directed high-magnitude cel-
lular immune responses at mucosal sites will more likely protect
against infection and post-infection virus replication. It remains
possible that the efficacy of RV144 may have been due in part to
the presence of vaccine-induced antibody and cellular immunity
in the genital mucosa.
More intriguing, however, is the fact that all the HIV-1 vaccine
candidates tested for efficacy showed modest immune responses
in preclinical and early stages of clinical evaluation but have shown
no efficacy in the longer term. Take for instance, the MRKAd5 vac-
cine that induced robust responses in majority of vaccinees but
failed to prevent HIV infection or post-infection viremia (47, 55).
Although this vaccine was not expected to prevent infection, the
fact that it did not attenuate disease course despite the observed
immune responses begs the question as to whether the current
measurements of evaluating vaccine immunogenicity during the
preclinical and Phase I clinical trials (193) are robust enough
to predict vaccine failure. Apart from the inevitable discrepan-
cies between animal models and humans, this might also per-
haps suggest qualitative and quantitative differences between the
vaccine-stimulated responses and those required to prevent HIV-1
acquisition at the first point of encounter (genitorectal mucosa).
Indeed, in addition to paucity of CD4+T cell responses, the CD8+
T cell responses in the MRKAd5 vaccinees were found to be of low
magnitude, narrowly directed, less polyfunctional, and targeted
mostly Pol and Nef (55), contrary to what has been correlated
with spontaneous HIV-1 control. Furthermore, as most vaccine-
stimulated responses are tested by IFN-γ ELISPOT in peripheral
blood samples, it could be though that potent responses are elicited
in the systemic compartment, their migration to mucosal portals
of entry where they are critical may be a limitation. Indeed, some
studies have revealed a lack of correlation in the magnitude, qual-
ity, breadth, and functional capacity of T cell responses between
blood (systemic) and mucosal samples (43–45). Thus, in addition
to induction of robust systemic antibody and cell-mediated immu-
nity, vaccine strategies that focus on generating local immune
responses within the genitorectal mucosa, such as the“prime-pull”
(194) approach may be more successful at reducing the replica-
tion and dissemination of transmitted founder viruses. Moreover,
it remains possible that other parameters of the mucosal immune
response such as proliferation, in vitro viral inhibition, and ADCC
could be important (74, 111, 195, 196). Thus, accurate correlates
of protection should include active sampling of mucosal com-
partments and measure several immunological and phenotypic
parameters, including expression of mucosal homing receptors
and ligands.
Recent studies document the antiviral potential of vaccine-
stimulated T cells against various HIV-1 isolates (58) or SIV
(SIVmac239 and SIVsmE660) (197, 198) using in vitro virus sup-
pression assays (VIA). The general expectation is that VIA (199,
200), which demonstrate active inhibition of the replication of
intact virus in vitro (or ex vivo) would correlate with in vivo inhi-
bition of HIV replication (198, 201), and would therefore be a
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more accurate prediction of vaccine efficacy. In fact the in vitro
antiviral inhibitory capacity of CD8+T cells measured by VIA was
shown to accurately predict CD4+ T cell loss during early HIV-1
infection (201). However, the in vitro VIA did not predict vaccine
efficacy or in vivo inhibition of virus replication in a challenge
SIV study in NHPs (197), suggesting that more robust markers to
predict vaccine efficacy are needed. Alternatively, this discrepancy
could be attributed to lower frequencies of vaccine-stimulated T
cells within the genital mucosa, and it might be that VIA per-
formed with T cells isolated from the genital mucosa will give a
better correlation with in vivo HIV or SIV control. Thus, studies
that assess mucosal B or T cell antiviral capacity, whether vaccine
stimulated (human and NHP) or HIV induced, for example in
LTNPs, elite controllers and HEPS will be important in informing
research aiming to identify correlates of vaccine efficacy.
On a completely separate platform, increased susceptibility to
HIV-1 acquisition in vaccinees in the STEP and Phambili studies
might to a certain extent reflect the dark side of vaccine-mediated
immune activation that may create readily available HIV-1 targets
(55, 202, 203). This hypothesis was proven in a challenge study
where immunized rhesus monkeys exhibiting higher frequencies
of IFN-γ secreting T cells were more susceptible to SIV infec-
tion (203). This strongly suggests that induction of sub-optimal
vaccine-specific T cells (without robust antiviral effector func-
tions) could increase the risk of HIV-1 acquisition in vaccinated
individuals. Other risk factors such as herpes simplex virus type 2
(HSV-2) infection may significantly alter the immune milieu in the
genitorectal mucosa (204–206) and affect HIV-1 vaccine efficacy.
Indeed, HSV2 infection correlated with a fivefold increased risk of
HIV-1 acquisition in heterosexual men in the HVTN505/Phambili
study (48) and in homosexual men in the STEP study (47). HSV2
infection subverts cellular immune responses directed to HIV-1
(205), disrupts mucosal integrity, and induces massive recruit-
ment of HIV-1 targets (CCR5+CD4+ T cells and immature DCs
expressing DC-SIGN) to the genitorectal mucosa (207). These
observations highlight the additional challenge to clearly define
benchmark features that distinguish protective versus detrimental
vaccine-induced immune cells that accelerate HIV-1 acquisition
and disease progression. This is more especially due to the seem-
ingly unavoidable paradox, where imprinting a mucosal homing
phenotype on vaccine-induced immune cells is critical to prevent
HIV-1 acquisition, but also poses a significant risk of increased
susceptibility.
BROADLY NEUTRALIZING ANTIBODIES ARE CRITICAL
DETERMINANTS FOR STERILIZING IMMUNITY
The occurrence of systemic and mucosal HIV-specific neutraliz-
ing IgG antibodies is also documented in LTNPs (135, 208–210),
where they were initially linked with slow disease progression.
However, recent studies indicate that their role in controlling
established infection is quite limited and that high titers and
breadth are in fact a result of higher virus loads (211). Indeed,
such bNAbs are frequently detected in a very small proportion
of HIV-infected individuals known as elite neutralizers (212), but
they do not prevent disease progression (213), presumably due
to rapid virus escape. Thus, a major limitation of antibodies is
the high escape rate, meaning that even with the most excellent
bNAbs, protection may only be transient as mutational escape
occurs within a relatively short time. Moreover, several studies
indicate that bNAbs are found at much lower levels among the
Elite and viremic controllers (142, 214, 215), and at comparatively
higher levels in chronic progressors (142), not only suggesting
a lack of influence on virus replication and disease progression
(211, 213), but most importantly also reinforcing the fact that
neutralization breadth increases with prolonged exposure to HIV.
These observations, together with the fact that bNAbs take several
years to develop, incited skepticism and questioning of the poten-
tial relevance of bNAbs in preventing HIV acquisition and disease
progression. Nonetheless, the possibility that bNAbs could achieve
virus neutralization and block virus entry if present within the
genital mucosa before infection, either by passive administration
or if induced by immunization has been a cause worth fighting for.
A large panel of bNAbs (both first and second generation) have
thus been extensively characterized (71), and some such as PG9
and PG16 which are found within the conserved domain of the
V1/V2 loop were shown to induce potent neutralizing activity on
70–80% of circulating HIV-1 isolates (66, 216). The CD4 binding
site monoclonal antibodyVRC01, in particular,displays very broad
neutralizing activity (>90%) against primary isolates of envelope
pseudoviruses (70). These monoclonal bNAbs have been quite
successful in animal studies, for instance, vaginal administration
of B12 or intravenous delivery of 2F5 and 4E10 mAbs protected
macaques from intravaginal or intrarectal SHIV challenges (217,
218), raising the possibility that bNAbs can attenuate HIV-1 acqui-
sition and disease progression. Indeed, this has been demonstrated
in recent passive transfer studies in NHPs showing that if present
at sufficient levels and well before virus challenge, then bNAbs
can in fact abort infection to achieve sterilizing immunity (77,
218–221). The main caveats making it difficult to extrapolate the
relevance of NHP studies to humans are (1) unlike natural HIV-1
infection, where individuals are exposed to diverse HIV-1 strains
with differing neutralization sensitivities, NHP studies often use
a homogeneous challenge virus that is usually highly susceptible
to neutralization. (2) Some NHP studies have used high doses of
antibodies that are unlikely to be attained by immunization. (3)
Some NHP studies use high doses of the challenge viruses, which
can significantly mask the vaccine-mediated protection. Nonethe-
less, several monoclonal bNAbs with potent neutralizing activity
such as the PGT, PG, and VRC series, among others (66, 70, 216)
afforded sterile protection at very low serum concentrations, even
with high-dose challenges (85, 219, 220, 222, 223). Furthermore,
bispecific bNAbs combining the inhibitory activity of an antibody
directed to domain 2 of human CD4 (ibalizumab) with either
PG9 (PG9-iMab) or PG16 (PG16-iMab) exhibited high potency
and neutralized 118 viruses at very low (picomolar) concentra-
tions (224). Hopefully, such remarkable neutralization breadth
and potency can be achieved in a clinical setting, via immunization
or passive administration.
These observations are very encouraging as they identify the
particular antibody target epitopes as excellent templates for vac-
cine design, and also shed some light on the threshold level of
antibodies required to achieve sterilizing immunity in humans.
This also raises hopes that antibody vaccines based on such potent
and bNAbs would achieve significant control of virus replication
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in infected individuals and possibly offer sterilizing immunity
in healthy vaccinated subjects. However, no vaccine has induced
bNAbs so far, and the only evidence that bNAbs could offer some
protection in humans comes from earlier clinical studies where
passive administration of the bNAbs, 2G12, 2F5, and 4E10 was
shown to transiently delay viral rebound after HAART cessa-
tion (225, 226), but the protection was very limited. In a recent
Phase I clinical trial of the modified trimeric V2-deleted envelope
vaccine, potent neutralizing antibodies were induced in human
volunteers, but these were of very limited breadth (227), despite
enhanced neutralization breadth in animal studies (228, 229).
Thus, the greatest challenge for antibody vaccines is to induce
bNAbs that are potent enough to recapitulate the neutralization
spectra observed in elite neutralizers and to neutralize many virus
isolates including the most resistant, heterologous tier-2 and tier-3
viruses. The remarkable efficacy of monoclonal bNAbs in the vast
majority of animal studies discussed here may partly be due to
intravenous delivery, which ensures broad anatomic dissemination
including the genitorectal mucosa. However, it is still uncertain
whether bNAbs induced by parenteral immunization will traverse
to the genitorectal mucosa, thus strongly arguing for immuniza-
tion strategies to induce potent bNAbs localized within or in close
proximity to the genitorectal mucosa.
EXPERIMENTAL HIV-1 VACCINES TARGETING MUCOSAL
SITES
HIV-1 mucosal vaccinology is still in its infancy and remains a
challenge despite the intense interest within the HIV/AIDS field. A
mucosal vaccine that interferes with HIV-1 attachment and blocks
subsequent steps including crossing of the epithelial barriers
within mucosal surfaces to infect target cells, while at the same time
inducing potent systemic antibody and cellular immunity would
have a greater potential for enhanced efficacy. Although several
HIV-1 vaccine candidates administered by intramuscular injec-
tion stimulate robust systemic immune responses in peripheral
blood, whether or not these vaccine-elicited T cells or antibody-
secreting plasma cells can migrate to the genitorectal mucosa is
not well documented. This is a fundamental requirement for a
successful HIV-1 vaccine, therefore immunization modalities that
either generate immune responses in situ, i.e., within the geni-
tal mucosa, or strategies that drive recruitment of systemically
induced vaccine-specific immune cells to the genital areas are
highly desirable. The quality of mucosally induced vaccine-specific
immune responses and the degree to which they can disseminate
to other anatomic compartments largely depends on the route of
vaccine administration (230–233), besides the properties of the
immunogen. Thus, it is important that vaccine delivery routes are
carefully selected or optimized in order to maximize immune con-
trol in multiple sites. Perhaps the most important delivery routes
are those that demonstrate potential to stimulate both antibody
and cellular responses in the genitorectal mucosa, as well as other
mucosal sites and within various systemic compartments. Some of
these characteristics have been traditionally attributed to mucosal
immunization including intranasal, intravaginal, intrarectal, and
oral or sublingual delivery routes (230, 234, 235). Possibly, deliv-
ery of a vaccine at one mucosal site may induce immunity at
peripheral mucosal sites via the common mucosal immune system
(236, 237), although this hypothesis is disputed by studies showing
compartmentalization of the mucosal immune network (238).
Despite the near consensus for mucosal delivery of immuno-
gens being the best way to trigger mucosal immune responses (230,
239), there are still controversies as to whether mucosal antigen
delivery alone can effectively induce systemic immune responses.
This is largely due to the tissue-specific imprinting of chemokine
receptors and adhesion molecules on immune cells following acti-
vation within mucosal inductive sites. Perhaps, the sublingual
vaccination route which has been shown to induce broadly dis-
seminated mucosal and systemic immune responses (230) may be
considered as a more suitable alternative for delivery of HIV vac-
cines. Intrarectal administration of a DNA/MVA vaccine encoding
HIV immunogens was also shown to elicit both systemic and
mucosal virus-specific immune responses that were associated
with delayed progression to AIDS following SHIV89.6P challenge
(240). Another possible alternative is to combine both intramuscu-
lar and intranasal delivery, a strategy that has been quite successful
in enhancing vaccine-induced HIV-specific immune responses
in both the systemic and vaginal compartments in NHP stud-
ies (241–243). These observations demonstrate that mucosally
delivered vaccines undoubtedly elicit local immune responses that
are capable of disseminating to other systemic compartments. In
the following sections, we highlight some of the studies which
have successfully employed mucosal vaccine delivery with or with-
out mucosal adjuvants to elicit potent immune responses in the
genitorectal mucosa.
MUCOSAL IMMUNIZATION WITHOUT ADJUVANTATION
Active mucosal immunization has been shown to induce potent
cell-mediated and antibody responses at the genital mucosa in
animal studies (244–246). In particular, intranasal vaccine deliv-
ery induces robust antibody and T cell immune responses in the
genital mucosa, possibly due to targeting of dendritic cells in mul-
tiple organs such as the respiratory system, the gut mucosa, and
the spleen (247, 248). Intranasal delivery of a number of HIV
vaccine approaches such as DNA, peptide, live bacterial, and viral
vectors induced strong CD8+ T cell responses and/or antibody
responses (comprising IgG and IgA and sometimes neutraliz-
ing antibodies in vaginal washes) in mice and macaques (233,
249–251). Very recently, studies in NHPs have demonstrated that
intranasal and oral vaccine administration routes were consistently
and significantly better than intramuscular administration, and
elicited mucosal and systemic immune responses that protected
rhesus macaques from disease progression following intrarectal or
vaginal challenges (252–256). These mucosal immunization routes
induced high-magnitude polyfunctional CD8+ and CD4+ T cells
in the rectum and vagina, which correlated with the extent of viral
control.
Although mucosal (intranasal or intrarectal) delivery of DNA
vaccines enhances vaccine-specific mucosal responses, it has been
suggested that the quality, longevity and peripheral distribution of
memory T cell responses in the genital mucosa could be improved
by systemic (or intravaginal) administration of live vaccines (231,
257, 258). Live recombinant vaccine delivery vectors introduced
via intramuscular, intrarectal, oral or intravaginal routes in a
prime-boost strategy induced robust HIV-specific T cell responses
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in the vaginal mucosa as well as in the spleen, possibly due to
active systemic infection that stimulates potent immune responses
(257). In this study, intravaginal delivery of attenuated recombi-
nant Listeria monocytogenes expressing Gag (rLm-gag) as a prime
in combination with replication-defective adenovirus serotype 5
(Ad5) expressing Gag (rAd5-gag) as a boost induced robust Gag-
specific CTL responses in the vaginal mucosa and these persisted
for at least 5 months. The persisting CTLs were of effector memory
phenotype and possessed strong cytotoxic activity which protected
against a vaccinia-Gag challenge.
Influenza virus targets the respiratory system and is thus well-
adapted for stimulating mucosal immunity. Therefore, recom-
binant influenza virus vectors expressing foreign genes effi-
ciently stimulate potent long-lasting antibody and T cell immune
responses in mucosal and systemic compartments (259–261).
Chimeric influenza virus expressing HIV-1 gp120 V3 loop pep-
tide (IHIGPGRAFTYTT) induced robust NAb and CTL responses
following mucosal immunization in mice (262). In a separate
study, intranasal delivery of recombinant influenza expressing
the gp41 ELDKWA epitope also stimulated persistent NAb and
IgA responses in nasal, vaginal, and intestinal secretions (263–
265). Moreover, H1N1 and H3N2 influenza viruses expressing
SIV CD8+ T cell epitopes induced T cells with the mucosal hom-
ing (α4β7) integrin following intranasal or intratracheal vaccine
delivery in pigtail macaques (266). Of particular relevance to
induction of long-lived vaccine-specific immunity by repeated
immunization, influenza virus vectors when combined with other
vectors in mucosal (intraperitoneal and intranasal) prime-boost
immunization protocols, have proven effective at priming HIV-
specific mucosal immune responses that could be augmented by
recombinant MVA in BALB/c mice (267). This demonstrates the
potential utility of influenza virus vectors in effective prime-boost
immunization regimens to generate mucosal immune responses
in the genitorectal draining lymph nodes to combat HIV infec-
tion. The possible limitation of influenza virus vectors is the
insert capacity which may limit the size of antigens that could
be delivered.
Several studies indicate that poxvirus vectors can also induce
mucosal immune responses to foreign antigens. In particular, some
studies have reported induction of immune responses in the geni-
torectal mucosa [as well as in the Peyer’s patches (PP) and lamina
propria], that controlled SHIV replication in mice and NHPs fol-
lowing mucosal immunization with recombinant vaccinia virus
(268–270). Mucosal (intranasal and intrarectal) delivery of non-
replicating rMVA vaccines in a DNA-prime and MVA-boost strat-
egy also induced robust antibody and cellular immune responses
in the systemic compartment as well as in the genitorectal mucosa,
which controlled SHIV replication and disease progression (240,
271). Mucosal vaccination with other poxvirus vectors including
NYVAC and ALVAC also induced antigen-specific responses in
mucosal compartments (272).
A number of studies also demonstrate induction of long-lived
mucosal immunity following systemic immunization with live
virus vectors such as Ad5 and NYVAC, owing to acquisition of
mucosal homing properties by vaccine-induced CD8+ and CD4+
T cells (272–275). In some cases, the immune responses elicited
following intramuscular delivery were superior or equivalent to
those elicited by mucosal immunization. Intramuscular delivery of
the SIV antigens; gag/pol or gag/pol/env by Ad35-prime followed
with Ad26-boost in rhesus macaques induced potent NAb and cel-
lular immune responses in the periphery and within the colorectal
mucosa (276). Both peripheral and mucosal immune responses,
especially Env-specific IgG correlated with reduced risk of SIVMAC
acquisition during intrarectal challenges. This is indeed very
encouraging and may obviate the need for the more invasive geni-
tal mucosal immunization methods (intravaginal and intrarectal),
although factors such as activation status and the inflammatory
state of the host could affect mucosal recruitment and retention,
as well as memory reactivation. Additionally, any impairment in
the migratory capacity of vaccine-induced immune cells, pos-
sibly because differential up-regulation or down-regulation of
mucosal homing integrins would significantly affect the biological
relevance of the vaccine in the genitorectal mucosa.
MUCOSAL IMMUNIZATION WITH ADJUVANTATION
Mucosal adjuvants such as the non-toxic B subunit of cholera
toxin (CTB) or heat labile toxin B subunit (LT-B) are known
to boost protective antibody and cellular immune responses fol-
lowing mucosal immunization, and could therefore impact sig-
nificantly on HIV-1 vaccine efficacy (244, 277). These mucosal
adjuvants have been very successful in a number of experimen-
tal animal studies. For instance, intrarectal immunization with
a synthetic peptide vaccine incorporating the mutant form of
heat labile toxin, LT(R192G), as an adjuvant induced mucosal
and systemic SIV-specific CTL responses that correlated with viral
clearance in challenge experiments (278). Furthermore, intranasal
co-administration of HIV-1 envelope antigens in a DNA/MVA or
MVA/MVA immunization together with cholera toxin (CT) signif-
icantly enhanced antibody and cellular immune responses in the
mucosa as well as systemic compartments (279). Other adjuvants
known to enhance mucosal immune responses include immuno-
stimulatory CpG motifs and pro-inflammatory cytokines such as
IL-1α, IL-12, and IL-18 (44, 244, 280, 281). CpG adjuvantation
in particular was shown to significantly enhance vaccine-induced
antibody and cellular immune responses following mucosal deliv-
ery and to provide protection from mucosal virus challenge (282–
284). The glycolipid α-GalCer also shows promise as a mucosal
adjuvant which could be used with DNA vaccines (285). The
use of non-replicating virosome vectors, known for their intrinsic
adjuvant properties and efficient targeting of antigen presenting
cells (286) may be another useful delivery platform to enhance
mucosal immune responses. Intramuscular and intranasal deliv-
ery of a gp41 subunit antigen grafted on virosomes was shown
to protect monkeys against SHIV challenge following induction
of vaginal IgA and IgG with potent transcytosis blockade activi-
ties as well as neutralizing and ADCC activities (43). Intriguingly,
protection of vaccinated animals was mediated by the mucosal
antibody activities and not the serum circulating HIV-1 antibod-
ies or bNAbs, suggesting that mucosal responses can prevent HIV
acquisition in the absence of other systemic responses including
bNAbs. Feasibility of the virosome delivery method for induction
of mucosal antibodies in humans has been recently demonstrated
in a Phase I proof-of-principle study using HIV-1 gp41-derived
peptides (287). In this study, both serum IgG and IgA, as well
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as vaginal and rectal IgG were induced, but neutralization activ-
ity was not detected. However, vaginal secretions were shown to
inhibit HIV-1 transcytosis, demonstrating potential to reduce HIV
acquisition.
Ultimately, the goal for mucosal HIV-1 vaccine delivery is to
generate local antibody and mucosal T cells with antiviral activ-
ities, but also with intrinsic ability to disseminate systemically in
order to combat HIV-1 infection and spread. Alternatively, the use
of tissue-specific adhesion molecules or chemokine-mediated site-
specific directed migration of vaccine-stimulated immune cells
from mucosal immune inductive sites to peripheral mucosal and
systemic effector sites (230, 288) may be useful delivery strategies
for HIV vaccines.
MUCOSAL HOMING MARKERS ON IMMUNE EFFECTOR
CELLS
The migration of effector/memory T cells and ASC such as those
that secrete IgA (IgA-ASC) to various extra-lymphoid tissues
including the gut and genitorectal mucosa is facilitated by specific
homing receptors on immune cells, together with their cognate
ligands, which are expressed in the destination tissues. Migration
to the gut for instance requires up-regulation of the chemokine
receptors CCR9 and CCR10, as well as the mucosal integrin α4β7
(289–292). The α4β7 integrin, also known as lymphocyte Peyer’s
patch adhesion molecule-1 (LPAM-1) is a mucosal homing recep-
tor that binds MAdCAM-1, a mucosal vascular addressin selec-
tively expressed on intestinal mucosal endothelium. CCL25, the
ligand for CCR9, is expressed mainly by small intestine endothe-
lial and epithelial cells (293, 294), while CCL27 and CCL28 (the
ligands for CCR10) are expressed in several mucosal tissues. Thus,
binding of these receptors to their respective ligands mediates
selective lymphocyte homing to and retention within the intesti-
nal lamina propria and the PP (295–298). Co-expression of CCR9
or CCR10 with α4β7 is therefore a characteristic phenotype of
gut homing immune cells. This guided migration is important
for tissue-targeted immune activities such as that demonstrated in
murine rotavirus infection, where memory/effector CD8+ T cells
expressing high levels of α4β7 (i.e., α4β7hiCD44hi) homed prefer-
entially to intestinal tissues and were more effective at pathogen
clearance compared to cells with α4β7loCD44hi phenotype (299).
Moreover, expression of gut homing receptors on CD4+ T cells
was shown to be important for mucosal immune reconstitution
following HAART, as failed reconstitution was linked to defective
homing (300).
While migration of vaccine-induced T and B cells to the gut is
crucial to prevent establishment of HIV-1 reservoirs and CD4+
T cell destruction (301), migration to the genitorectal mucosa
is critical for preventing HIV-1 acquisition. Although migra-
tion to these distinct mucosal sites may be governed by distinct
signals, homing to the genitorectal mucosa also requires a B7
integrin, αEβ7 (CD103), which is known to mediate lympho-
cyte recruitment to various mucosal tissues (including the genital
mucosa) by binding to epithelial cadherin (E-cadherin) (302–
305). A recent study reported isolation of a functional subset
of HIV-specific CD8+CD103+IFN-γ+ T cells in samples from
the cervical mucosa of HIV-infected individuals (306). CXCR3
expression is up-regulated following lymphocyte activation, and
allows migration of CXCR3+ cells to inflamed sites where the cog-
nate ligands, CXCL9 and CXCL10, are up-regulated in response to
inflammatory stimuli. Thus, expression of CD103 and CXCR3 by
activated B and T cells is likely to direct their migration to the
genitorectal mucosa, especially if some degree of inflammation is
induced (194).
Naïve lymphocytes express CD62L and CCR7, the major lymph
node homing markers, which allow them to circulate through
various lymphoid organs, under homeostatic conditions. Upon
antigen encounter, they differentiate into activated cells express-
ing unique adhesion receptors that are imprinted based on the
site of antigen exposure (307). For instance, systemic antigen
exposure can confer multiple homing signatures, whereas oral
exposure preferentially induces higher levels of gut homing recep-
tors (289). This could in part be due to increased expression of
retinoic acid receptors on dendritic cells and macrophages in gut-
associated lymphoid tissues [PP, mesenteric lymph nodes (MLN)
and intestinal lamina propria] which facilitate imprinting of gut
homing properties on activated T and B cells by generating retinoic
acid to up-regulate CCR9, CCR10, and α4β7 (308–311). Thus,
targeting delivery of HIV-1 antigens for activation within the
PP and MLN via mucosal immunization may lead to induction
of αEβ7hi/CD44hi, α4β7hi/CCR9+, or α4β7hi/CCR10+ immune
cells with the ability to access multiple mucosal compartments,
including the genital and rectal mucosa.
FACTORS THAT LIMIT ASSESSMENT OF IMMUNE
RESPONSES IN THE GENITORECTAL MUCOSA
Some of the difficulties arising from studying mucosal sites
include the heterogeneity in frequencies and distribution of vari-
ous immune cell phenotypes, especially in the female genital tract.
For instance, the frequency of CD4+ and CD8+ T cells, B cells
and NK cells, as well as other antigen presenting cells varies sig-
nificantly between the lower vaginal mucosa, the ectocervix, and
the transformation zone (312). Furthermore, these vary signifi-
cantly between individuals, owing to factors such as the menstrual
cycle and hormonal regulation of the immune system, including
levels of IgG and IgA antibodies (209, 312, 313). Such inconsis-
tencies, especially in the integrity of the protective mucus barrier
(314–316) and the frequency of activated HIV target cells have
great influence on HIV acquisition and control (317–319). Other
obstacles relate to the invasiveness of mucosal sampling procedures
to obtain cervi-covaginal lavage, swabs, or rectal biopsies and the
accompanying time-consuming procedures for isolation of cells
from the biopsies (320). Furthermore, the cell yields are charac-
teristically very low and inadequate for comprehensive functional
analysis studies. Despite these challenges, procedures to collect,
process, and analyze mucosal samples in clinical trials are actively
being developed by groups such as the HIV Vaccine Trials Network
(HVTN) and the Mucosal Immunology Group (MIG). With such
collaborative efforts, several mucosal samples including semen,
saliva, rectal and cervical secretions, as well as rectal and foreskin
biopsies can now be collected and tested. Sample collection meth-
ods (including cups, adsorbent wicks, or sponges for vaginal and
rectal secretions) as well as cryopreservation techniques and ultra-
sensitive analytical assays that utilize minimal sample volumes and
cell numbers are being developed and optimized.
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES
A successful HIV-1 vaccine will have to stimulate both antibody
and cell-mediated immune responses within the mucosal sites of
transmission and in blood, while concurrently avoiding recruit-
ment of activated HIV-1 target cells to the genital mucosa. Owing
to the enormous hurdles relating to mucosal sampling methodolo-
gies and limited sample volumes, immune correlates of protection
against HIV-1 in the genital mucosa have not been routinely tested
during clinical trials that evaluate immunogenicity and vaccine
efficacy (165). However, the field is progressing steadily and it is
anticipated that routine assessment of mucosal immune responses
induced by immunization will be incorporated in clinical trials.
Given the detection of antibody and cellular immune responses
that correlate with protection from HIV-1 acquisition as observed
in HEPS and from disease progression as seen in aviremic and
viremic controllers, together with vaccine-induced responses in
the STEP and RV144 trials (and the ongoing RV152 follow-up
study), there indeed are several clues of the sort of immune
responses that would correlate with HIV-1 vaccine efficacy. All evi-
dence assessed to date indicates that the most successful strategy
will induce high titers of both bNAbs and non-neutralizing anti-
bodies to block mucosal transmission of multiple HIV-1 isolates,
together with a strong polyfunctional T cell immune response
with high antiviral capacity to rapidly target and kill any HIV-
1 infected cells at the genitorectal mucosa and prevent systemic
spread or establishment of latent reservoirs, before virus diver-
sification. Above all, to attain desirable efficacy levels, vaccine-
stimulated responses will indeed have to be present within the
genitorectal mucosa prior to HIV-1 exposure. And to maintain
sustained HIV immune surveillance, vaccines will need to induce
stable, long-lasting B and T cell memory within the genitorec-
tal mucosa, perhaps by employing vectored immuno-prophylaxis
(85) or sustained antigen release (321) strategies.
As far as vaccine delivery modalities are concerned, several
proof-of-principle studies highlight the feasibility of inducing
potent immune responses in the systemic and mucosal com-
partments by delivering vaccines through intranasal, intravaginal,
intrarectal, and oral/sublingual routes in various combinations
of heterologous prime-boost immunization strategies. Although
quite few, such strategies have shown improved vaccine immuno-
genicity in human studies and the efficacy of these mucosally
redirected immune responses needs to be evaluated in larger clini-
cal trials. Possible concerns about induction of tolerance following
mucosal immunization (288) will need to be addressed, although
this could be overcome by initial systemic priming followed with
mucosal boosting, or perhaps by use of carefully designed vaccine
delivery and dosage regimens. Moreover, experimental studies in
animals demonstrate robust responses following mucosal priming
and mucosal boosting (241, 243), suggesting that the benefits of
mucosal vaccine delivery may by far outweigh the risk of tolerance
induction.
It remains possible that live viral vectors will be the most effec-
tive delivery method to induce potent mucosal immune responses
following the most preferred, non-invasive parenteral delivery.
However, until this is tested extensively and found comparable
to or better than mucosal vaccines, the search for suitable deliv-
ery platforms to induce protective T cell and antibody responses
and to provide a local immune barrier at the genital mucosa must
continue. Perhaps the most practical way to ensure that sufficient
numbers of protective CTLs home to the genital mucosa follow-
ing parenteral vaccine delivery is the innovative “prime and pull”
approach that was proposed by Shin and Iwasaki (194). The poten-
tial of this strategy was proven in mice studies where priming
with a model HSV-2 vaccine elicit systemic T cell responses, fol-
lowed by the guided migration of these T cells by applying CXCL9
and CXCL10 chemokines in the vaginal mucosa, thus leading to
increased recruitment of CD8+ and CD4+ T cells (194). This
immunization strategy generated a local memory T cell pool which
was stable and persisted for a long time. However, when tested in
the context of HIV vaccines, the prime-pull strategy achieved only
a modest effect on local and systemic antibody responses (322).
Despite this, the enormous potential of this strategy to significantly
enhance the magnitude and longevity of HIV vaccine-induced T
and B cells in the genital mucosa warrants further testing.
In conclusion, the data available in the field thus far point to
the imminent possibility of a vaccine that can stimulate the greatly
desired protective mucosal and systemic immune responses. It
might be that a carefully selected combination of immunogens,
adjuvants, delivery vectors, and immunization routes may pos-
sibly yield an HIV-1 vaccine that induces optimal activation of
the innate immune system and elicit protective antibody and T
cell responses in both the mucosal and systemic compartments.
So far, mucosal immunization seems to hold promise as the ulti-
mate modality to ensure sustained levels of potent antibody and
cellular immune responses at the genital mucosa, where they are
required to arrest initial breakthrough infections. Moreover, since
systemic responses do not accurately represent local immunity at
the genitorectal mucosa, comprehensive immuno-functional and
phenotypic characterization of the mucosal anti-HIV-1 immune
response that correlates with in vivo virus inhibition, together with
the mechanisms involved, will be crucial to the design of an effica-
cious vaccine for HIV-1. These will include accurate quantification
of threshold titers of the mucosal antibody and T cell responses
that would be sufficient to prevent infection.
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